.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Boehringer Ingelheim
McKesson
Harvard Business School
QuintilesIMS
Farmers Insurance
McKinsey
Healthtrust
Merck
Daiichi Sankyo

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,062,652

« Back to Dashboard

Which drugs does patent 8,062,652 protect, and when does it expire?


Patent 8,062,652 protects SUPPRELIN LA and is included in one NDA.

This patent has three patent family members in three countries.

Summary for Patent: 8,062,652

Title:Compositions and methods for treating precocious puberty
Abstract: The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP).
Inventor(s): Kuzma; Petr (Princeton, NJ)
Assignee: Endo Pharmaceuticals Solutions Inc. (Chadds Ford, PA)
Application Number:11/155,822
Patent Claim Types:
see list of patent claims
Use; Formulation; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Endo Pharm
SUPPRELIN LA
histrelin acetate
IMPLANT;SUBCUTANEOUS022058-001May 3, 2007RXYesYes► Subscribe► Subscribe METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,062,652

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office1773293► Subscribe
Canada2570960► Subscribe
World Intellectual Property Organization (WIPO)2006009801► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Covington
Cerilliant
Express Scripts
US Army
Citi
UBS
Cantor Fitzgerald
Chubb
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot